Berkowitz, Noah

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet

Tuberous Sclerosis Complex ResearchEpilepsy research and treatment

Cited by 764

Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors: Phase 1 Trial of EZN2208

Norris, R. E., Shusterman, S., Gore, L., Muscal, J. A., Macy, M. E., Fox, E., Berkowitz, N., Buchbinder, A., & Bagatell, R. (2014) · Pediatric Blood & Cancer

Cancer therapeutics and mechanismsPharmaceutical studies and practices

Cited by 38

Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).

Osborne, C. R. C., O'Shaughnessy, J., Holmes, F. A., Kim, H. S., Kocs, D. M., Steinberg, M. S., Richards, P. D., Vukelja, S. J., Berkowitz, N. C., & Buchbinder, A. (2012) · Journal of Clinical Oncology

Cancer Treatment and PharmacologyCancer therapeutics and mechanisms

Cited by 10

Abstract LB-407: Down-modulation of mRNA by EZN-2968, an hypoxia-inducible factor-1α (HIF-1α) mRNA antagonist, administered in adult patients with advanced solid tumors

Cohen, R. B., Olszanski, A., Figueroa, J., Hurwitz, H., Lokiec, F. M., Rezaï, K., Berkowitz, N., & Buchbinder, A. (2011) · Cancer Research

Cancer, Hypoxia, and MetabolismRNA Interference and Gene Delivery

Cited by 1